American Enterprise Institute (AEI) president Arthur C. Brooks has announced that AEI scholar Leon R. Kass, M.D., is the recipient of AEI’s 2012 Irving Kristol Award. Dr. Kass will receive the award and deliver the Irving Kristol Lecture at AEI’s annual dinner on Wednesday, May 2, 2012, at the National Building Museum in Washington, D.C.

Drug makers aren't chasing blockbusters like Lipitor anymore, or uncovering compounds the same way.

As scientists confront the challenge of how to regulate plasticizers—chemicals that make plastics soft, transparent and durable—the European Union is moving towards a model that US regulators should emulate.

A poignant story in Thursday’s Boston Globe describes how the O’Donnell family of Boston channeled their love of a son, Joey, who died tragically at the age of 12 from cystic fibrosis, into a successful mission to develop impactful new treatments for this terrible affliction.

For the last decade, as the biopharmaceutical industry has struggled — largely unsuccessfully — to live up to its anticipated potential, a litany of experts, analysts, participants, and commentators have offered up their diagnosis and treatment for pharma’s productivity problem.

The basic question they’re all trying to solve: how can...

While controversy has raged over the Food and Drug Administration’s (FDA) handling of drug safety, a lower-profile but equally important debate has centered on the FDA’s role in the development and commercialization of the most innovative kinds of new drug treatments for cancer and other conditions that have long defied...

The 1984 Hatch-Waxman Act created a streamlined path for generic drugs to reach the market after pioneer drug patents expire. The result has been the most vigorous and competitive generic drug market in the world, but the Hatch-Waxman Act does not apply to most biologics. Isolated from a variety of...

While controversy has raged over the Food and Drug Administration's (FDA) handling of drug safety, a lower-profile but equally important debate has centered on the FDA's role in the development and commercialization of the most innovative kinds of new drug treatments for cancer and other conditions that have long defied...